Dr. Hockfield is President Emerita, Professor of Neuroscience, and a member of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. From 2004 to 2012, she served as the sixteenth President of MIT, the first life-scientist and the first woman in that role. As President, Hockfield strengthened the foundations of MIT’s finances and campus planning while advancing Institute-wide programs in sustainable energy and the convergence of the life, physical and engineering sciences, with impact across the region, the nation and around the world. She helped shape national policy for energy and next-generation manufacturing. She was appointed by President Obama in 2011 to co-chair the steering committee of the Advanced Manufacturing Partnership and served as a member of a Congressional Commission evaluating the Department of Energy laboratories in 2015. As a biologist, she pioneered the use of monoclonal antibody technology in brain research, identifying proteins through which neural activity early in life affects brain development.
Before joining MIT as its president, she was named the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences (1998-2002), and Provost (2003-2004) at Yale University. In all her roles she has advanced opportunities for women and minorities. She studied at the University of Rochester and Georgetown University and researched the NIH and UCSF before joining the faculty at the Cold Spring Harbor Laboratory and then Yale. She is the past president and chairman of AAAS and currently is a director of the Charles Stark Draper Laboratory, Partners HealthCare System, and Fidelity Non-Profit Management Foundation. She is a life member of the MIT Corporation and a board member of the Belfer Center at the Harvard Kennedy School. She recently authored, The Age of Living Machines: How Biology Will Build the Next Technology Revolution, a popular science introduction to the convergence of biology and engineering technologies in the 21st century.
For a complete bio on Dr. Hockfield, click here.
To learn more about The Age of Living Machines, click here.
Dr. Fajgenbaum is an Assistant Professor of Medicine in the Division of Translational Medicine & Human Genetics at the University of Pennsylvania, the Co-Founder & Executive Director of the Castleman Disease Collaborative Network (CDCN), and Associate Director, Patient Impact of the University of Pennsylvania's Orphan Disease Center. Dr. Fajgenbaum is also a member of Forbes Magazine's 2015 "30 Under 30" healthcare list, Senior Fellow of the Leonard Davis Institute for Health Economics, and Fellow of the College of Physicians of Philadelphia.
Dr. Fajgenbaum co-founded the CDCN in 2012 to accelerate research and treatments for Castleman Disease through global collaboration, strategic investment in high impact research, and patient engagement. His research has initiated a paradigm shift in how doctors research and treat Castleman Disease. Dr. Fajgenbaum is working to create a blueprint for accelerating research for more diseases.
Dr. Fajgenbaum is also the Co-Founder and former Board Chair of the National Students of AMF Support Network, a non-profit organization dedicated to supporting grieving college students. AMF has reached 3,000+ students on 200+ college campuses nationwide. He recently co-authored "We Get It," a book for grieving college students and those who wish to support them.
Dr. Fajgenbaum's work has been highlighted by the New York Times, Science, Today Show, Reader's Digest, Everylife Foundation (2016 RareVoice: Federal Advocacy Award from Rare Disease Legislative Advocates), Global Genes (2015 RARE Champion of Hope: Science award by Global Genes), and the University of Colorado (2013 Distinguished Service Award). Dr. Fajgenbaum completed his MBA at Wharton, where he was awarded the Joseph Wharton Award, Core Value Leadership Award, Kissick Scholarship, Eilers Award, Mandel Fellowship, and Commencement Speaker. Dr. Fajgenbaum earned his MD from the Raymond & Ruth Perelman School of Medicine at the University of Pennsylvania, where he was a 21st Century Gamble Scholar. He studied for an MSc in Public Health from the University of Oxford as the 2007 Joseph L. Allbritton Scholar. He received a BS in Human Sciences with Distinction from Georgetown University, where he was USA Today Academic All-USA First Team. Dr. Fajgembaum recently wrote Chasing My Cure, a memoir describing how he used his medical training and crowdsourcing among patients and researchers to tackle Castleman’s disease, which eventually led to effective therapy.
As a global organization, Lonza is focused on achieving the strategic vision of being the world's leading, integrated solutions provider for its pharma and consumer healthcare and nutrition customers all along the healthcare continuum.
The company serves that continuum and certain other targeted markets through a wide range of businesses in its Lonza Pharma Biotech & Nutrition and Specialty Ingredients segments. The core competitive advantages that span these groups are advanced manufacturing and quality-control systems, superior regulatory expertise, in-depth market knowledge, extensive technical-customer support, and strong R&D capabilities.
Headquartered in Basel, Switzerland, Lonza has more than 100 sites and approximately 15,500 full-time employees worldwide. The company’s businesses benefit from global supply chains, but Lonza also has the flexibility to address regional and even local marketplace needs.
This prestigious honor is in recognition of Lonza’s outstanding leadership as a provider to life science research and industries. For over a decade, NDRI has been privileged to support the vital contributions Lonza makes to advancing discovery to improve health across the globe. NDRI continues to work with Lonza to meet the dynamic needs of all sectors of the research ecosystem - academia, industry, and government.
To learn more about Lonza, click here to visit their website.
Gift of Life Donor Program is the largest organ procurement organization (OPO) in the United States, leading the nation in the number of organ donors since 2008. Serving more than 11.2 million people across the eastern half of Pennsylvania, southern New Jersey, and Delaware, we help and heal lives by coordinating the recovery and distribution of organs and tissues used in life-saving and life-enhancing transplants.
Headquartered in Philadelphia, Pa., Gift of Life serves as a critical link between individuals and families who make the generous decision to donate organs and tissues, and those who need a transplant.
Gift of Life is part of the nationwide organ and tissue sharing network run by the United Network for Organ Sharing (UNOS). Since their inception in 1974, they have coordinated more than 47,000 organ transplants and approximately one million tissue transplants.
Since our founding, the National Disease Research Interchange (NDRI) has supported the progress of scientific research by partnering with organ procurement organizations (OPOs), tissue banks, eye banks, hospitals and independent recovery technicians to recover and distribute human tissue and organs to approved research projects. Gift of LIfe's partnership with NDRI provides donors and their families a powerful way to leave a meaningful legacy through research.
Click here to learn more about Gift of Life.